By comparison, Mounjaros pivotal SURMOUNT-1 trial reported up to around 22.5% mean weight loss at 72 weeks, and Wegovys STEP-1 trial reported around 14.9% at 68 weeks
Loss of pancreatic function can show up clinically as diabetes or as a disease called exocrine pancreatitic insufficiency where the body cannot make enough digestive enzymes and food is not properly absorbed
Common GLP-1 RAs include: Tirzepatide (Mounjaro, Zepbound) Orforglipron (Foundayo) Semaglutide (Ozempic, Wegovy) Liraglutide (Victoza, Saxenda) Dulaglutide (Trulicity) Exenatide (Byetta, Bydureon) Are GLP-1 medications safe during pregnancy
Si le interesa reducir gradualmente o espaciar las dosis, el primer paso es hablar con su proveedor de atencin
Higher dose exploration (4.5mg trials) Rationale for testing 4.5mg: Investigate maximum tolerable dose Determine if higher = better weight loss Establish safety ceiling Results at 4.5mg weekly: Weight loss: ~12% (vs 10% at 2.4mg) Incremental benefit: Only 2% additional loss Side effects: Significantly worse nausea/vomiting Dropout rate: Higher than 2.4mg Clinical verdict: 4.5mg not recommended for routine use Risk-benefit ratio unfavorable 2.4mg remains optimal Some individuals may tolerate 3.0mg as compromise CagriSema combination dosing trials REDEFINE-1 protocol: Semaglutide: 2.4mg weekly (standard titration over 16 weeks) Cagrilintide: 2.4mg weekly (12-week titration) Both given as separate injections Started simultaneously from week 1 Semaglutide escalation (standard): Weeks 1-4: 0.25mg Weeks 5-8: 0.5mg Weeks 9-12: 1.0mg Weeks 13-16: 1.7mg Week 17+: 2.4mg Cagrilintide escalation (when combined): Weeks 1-4: 0.6mg Weeks 5-8: 1.2mg Weeks 9-12: 1.8mg Week 13+: 2.4mg Results: 15.6% average weight loss (68 weeks) Superior to either alone Side effects manageable with slow titration Combination well-tolerated See our cagrilintide and semaglutide combination guide and semaglutide dosage calculator
.jpg)
